Vermact 12mg Tablet

Ivermectin is used for specific parasitic infections, with approved indications differing by country.

• Intestinal strongyloidiasis: An infection caused by Strongyloides stercoralis.

• Onchocerciasis: Also called river blindness; ivermectin reduces the microfilariae responsible for symptoms but does not kill adult Onchocerca worms.

• Scabies — Off-label use: Oral ivermectin is not FDA-approved for scabies in the U.S., although CDC guidance recognizes it as an oral treatment option under appropriate clinical supervision.

• Certain other parasitic infestations: Ivermectin may also be prescribed for selected conditions under local clinical guidance.

The correct indication should be established before treatment because not all parasitic infections respond to ivermectin.

Ivermectin belongs to the anthelmintic class of medicines. It acts selectively on parasite nerve and muscle cells by binding to glutamate-gated chloride channels. This increases chloride permeability, causing hyperpolarization and paralysis of susceptible parasites, eventually leading to their death.

Its activity is selective because mammals do not have the same glutamate-gated chloride channels. Ivermectin is active against certain life stages of susceptible parasites, but it does not eliminate adult Onchocerca volvulus worms.

Ivermectin dosing is weight-based, so a 12mg tablet should not be treated as a universal single dose.

Condition	Label-based general guidance
Strongyloidiasis	Approximately 200 micrograms/kg as a single oral dose in U.S. labeling
Onchocerciasis	Approximately 150 micrograms/kg as a single oral dose
Scabies	Off-label in the U.S.; CDC recommends 200 micrograms/kg per dose, generally repeated 7–14 days later
Children under 15kg	Safety and effectiveness have not been established for U.S. labeled oral ivermectin
12mg tablet	The appropriate number of tablets depends on the prescribed weight-based regimen

These are general references rather than an individual dosing recommendation. The prescribed dose depends on body weight, infection, age, medical history, other medicines and local treatment guidance.

For the FDA-labeled uses of ivermectin, tablets are taken on an empty stomach with water. Follow the prescription and product leaflet supplied with Vermact rather than changing the timing or dose yourself.

• Swallow the tablet with water as directed.

• Do not take additional tablets because symptoms have not improved immediately.

• For strongyloidiasis, follow-up stool examinations may be needed to confirm clearance.

• For onchocerciasis, repeated medical follow-up and retreatment may be required because ivermectin does not kill adult worms.

• For off-label scabies treatment, CDC guidance recommends taking oral ivermectin with food, which differs from the fasting instruction used in the U.S. ivermectin label. Follow the regimen specifically prescribed for the condition being treated.

Common ivermectin adverse effects can include dizziness, nausea, vomiting, diarrhea, abdominal discomfort, weakness, sleepiness, tremor, itching and rash.

Important considerations include:

• Warfarin: Rare reports describe increased INR when ivermectin is used with warfarin; appropriate monitoring may be needed.

• Loa loa exposure: People with heavy Loa loa infection can develop serious encephalopathy after ivermectin. This is particularly important for people who have lived in or travelled through endemic areas of West or Central Africa.

• Other medicines: Tell the prescriber about prescription medicines, OTC products, vitamins and supplements before taking ivermectin.

• Neurological symptoms: Rare serious neurotoxicity, including altered consciousness, confusion and seizures, has been reported.

Do not use Vermact if you have a known hypersensitivity to ivermectin or any ingredient in the product. Ivermectin should be used only under appropriate medical guidance because the correct dose is determined by the infection and body weight. Safety and effectiveness of labeled oral ivermectin have not been established in children weighing less than 15kg.

Pregnancy requires particular caution: U.S. prescribing information states that adequate controlled studies in pregnant women are lacking and that ivermectin should not be used during pregnancy because safety has not been established. Ivermectin passes into breast milk at low concentrations, so treatment during breastfeeding requires an individual risk-benefit assessment.

People with significant exposure to Loa loa-endemic areas of West or Central Africa should be assessed before ivermectin treatment because heavy loiasis can result in severe or fatal encephalopathy. Seek urgent medical care for seizures, confusion, difficulty walking, loss of consciousness, severe allergic symptoms, or serious skin reactions.

Do not use veterinary ivermectin products in humans, and do not take more tablets than prescribed.

This information is for general education and does not replace advice from a doctor, pharmacist or qualified healthcare professional.